References
1. Sciarra A, Gentilucci A, Silvestri I, et al. Androgen receptor
variant 7 (AR-V7) in sequencing therapeutic agents for castratrion
resistant prostate cancer: A critical review. Medicine
(Baltimore). 2019;98(19):e15608.
2. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal
complications on patients’ quality of life, mobility, and functional
independence. Supportive care in cancer : official journal of the
Multinational Association of Supportive Care in Cancer.2008;16(8):879-889.
3. Sciarra A, Gentilucci A, Salciccia S, et al. Psychological and
functional effect of different primary treatments for prostate cancer: A
comparative prospective analysis. Urologic oncology.2018;36(7):340.e347-340.e321.
4. Kerr C. (223)Ra targets skeletal metastases and spares normal tissue.The Lancet Oncology. 2002;3(8):453.
5. De Vincentis G, Follacchio GA, Frantellizzi V, et al.
223Ra-dichloride therapy in an elderly bone metastatic
castration-resistant prostate cancer patient: a case report presentation
and comparison with existing literature. Aging Clinical and
Experimental Research. 2017;30(6):677-680.
6. Du Y, Carrio I, De Vincentis G, et al. Practical recommendations for
radium-223 treatment of metastatic castration-resistant prostate cancer.Eur J Nucl Med Mol Imaging. 2017;44(10):1671-1678.
7. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and
survival in metastatic prostate cancer. The New England journal of
medicine. 2013;369(3):213-223.
8. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of
metastatic bone cancer: a systematic review. The Lancet Oncology.2005;6(6):392-400.
9. Wong WW, Anderson EM, Mohammadi H, et al. Factors Associated With
Survival Following Radium-223 Treatment for Metastatic
Castration-resistant Prostate Cancer. Clin Genitourin Cancer.2017;15(6):e969-e975.
10. Prelaj A, Rebuzzi SE, Buzzacchino F, et al. Radium-223 in patients
with metastatic castration-resistant prostate cancer: Efficacy and
safety in clinical practice. Oncol Lett. 2019;17(2):1467-1476.
11. Fizazi K, Massard C, Smith M, et al. Bone-related Parameters are the
Main Prognostic Factors for Overall Survival in Men with Bone Metastases
from Castration-resistant Prostate Cancer. Eur Urol.2015;68(1):42-50.
12. Hague C, Logue JP. Clinical experience with radium-223 in the
treatment of patients with advanced castrate-resistant prostate cancer
and symptomatic bone metastases. Therapeutic advances in urology.2016;8(3):175-180.
13. Frantellizzi V, Farcomeni A, Follacchio GA, et al. A 3-variable
prognostic score (3-PS) for overall survival prediction in metastatic
castration-resistant prostate cancer treated with
(223)Radium-dichloride. Ann Nucl Med. 2018;32(2):142-148.
14. Cella DF, Cherin EA. Quality of life during and after cancer
treatment. Comprehensive therapy. 1988;14(5):69-75.
15. Fiteni F, Vernerey D, Bonnetain F, et al. Prognostic value of
health-related quality of life for overall survival in elderly
non-small-cell lung cancer patients. European journal of cancer
(Oxford, England : 1990). 2016;52:120-128.
16. Fournier E, Jooste V, Woronoff AS, Quipourt V, Bouvier AM, Mercier
M. Health-related quality of life is a prognostic factor for survival in
older patients after colorectal cancer diagnosis: A population-based
study. Digestive and liver disease : official journal of the
Italian Society of Gastroenterology and the Italian Association for the
Study of the Liver. 2016;48(1):87-93.
17. Steel JL, Geller DA, Robinson TL, et al. Health-related quality of
life as a prognostic factor in patients with advanced cancer.Cancer. 2014;120(23):3717-3721.
18. Karvonen-Gutierrez CA, Ronis DL, Fowler KE, Terrell JE, Gruber SB,
Duffy SA. Quality of life scores predict survival among patients with
head and neck cancer. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology.2008;26(16):2754-2760.
19. Baldari S, Boni G, Bortolus R, et al. Management of metastatic
castration-resistant prostate cancer: A focus on radium-223: Opinions
and suggestions from an expert multidisciplinary panel. Critical
Reviews in Oncology/Hematology. 2017;113:43-51.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization
for Research and Treatment of Cancer QLQ-C30: a quality-of-life
instrument for use in international clinical trials in oncology.Journal of the National Cancer Institute. 1993;85(5):365-376.
21. Zeng L, Chow E, Bedard G, et al. Quality of life after palliative
radiation therapy for patients with painful bone metastases: results of
an international study validating the EORTC QLQ-BM22. Int J Radiat
Oncol Biol Phys. 2012;84(3):e337-342.
22. De Vincentis G, Monari F, Baldari S, et al. Narrative medicine in
metastatic prostate cancer reveals ways to improve patient awareness &
quality of care. Future oncology (London, England).2018;14(27):2821-2832.
23. Fayers P, Bottomley A. Quality of life research within the EORTC-the
EORTC QLQ-C30. European Organisation for Research and Treatment of
Cancer. European journal of cancer (Oxford, England : 1990).2002;38 Suppl 4:S125-133.
24. McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The
relationship between quality of life (EORTC QLQ-C30) and survival in
patients with gastro-oesophageal cancer. Br J Cancer.2008;98(5):888-893.
25. Roncolato FT, Gibbs E, Lee CK, et al. Quality of life predicts
overall survival in women with platinum-resistant ovarian cancer: an
AURELIA substudy. Annals of oncology : official journal of the
European Society for Medical Oncology. 2017;28(8):1849-1855.
26. Greimel E, Bottomley A, Cull A, et al. An international field study
of the reliability and validity of a disease-specific questionnaire
module (the QLQ-OV28) in assessing the quality of life of patients with
ovarian cancer. European journal of cancer (Oxford, England :
1990). 2003;39(10):1402-1408.
27. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study
of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific
module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of
Life Group. European journal of cancer (Oxford, England : 1990).2000;36(14):1796-1807.
28. Guo SS, Hu W, Chen QY, et al. Pretreatment quality of life as a
predictor of survival for patients with nasopharyngeal carcinoma treated
with IMRT. BMC cancer. 2018;18(1):114.
29. Coleman RE. Clinical features of metastatic bone disease and risk of
skeletal morbidity. Clinical cancer research : an official journal
of the American Association for Cancer Research. 2006;12(20 Pt
2):6243s-6249s.
30. Chow E, Bottomley A. Understanding the EORTC QLQ-BM22, the module
for patients with bone metastases. Expert review of
pharmacoeconomics & outcomes research. 2009;9(5):461-465.
31. Sartor O, Vogelzang NJ, Sweeney C, et al. Radium-223 Safety,
Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First
U.S. Experience from an Expanded Access Program. The oncologist.2018;23(2):193-202.
32. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic
significance of patient-reported outcomes in cancer clinical trials.Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2008;26(8):1355-1363.
33. Montazeri A. Quality of life data as prognostic indicators of
survival in cancer patients: an overview of the literature from 1982 to
2008. Health and quality of life outcomes. 2009;7:102.
34. Mendez LC, Raman S, Wan BA, et al. Quality of life in responders
after palliative radiation therapy for painful bone metastases using
EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort.Annals of palliative medicine. 2017;6(Suppl 1):S65-s70.
35. McNamara MA, George DJ. Pain, PSA flare, and bone scan response in a
patient with metastatic castration-resistant prostate cancer treated
with radium-223, a case report. BMC cancer. 2015;15:371.
36. De Vincentis G, Follacchio GA, Frantellizzi V, Liberatore M,
Monteleone F, Cortesi E. Prostate-Specific Antigen Flare Phenomenon
During 223Ra-Dichloride Treatment for Bone Metastatic
Castration-Resistant Prostate Cancer: A Case Report. Clinical
Genitourinary Cancer. 2016;14(5):e529-e533.
37. EuroQol–a new facility for the measurement of health-related
quality of life. Health policy (Amsterdam, Netherlands).1990;16(3):199-208.
38. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating
clinically meaningful changes for the Functional Assessment of Cancer
Therapy–Prostate: results from a clinical trial of patients with
metastatic hormone-refractory prostate cancer. Value in health :
the journal of the International Society for Pharmacoeconomics and
Outcomes Research. 2009;12(1):124-129.
39. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of
Cancer Therapy scale: development and validation of the general measure.Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 1993;11(3):570-579.
40. Nilsson S, Cislo P, Sartor O, et al. Patient-reported
quality-of-life analysis of radium-223 dichloride from the phase III
ALSYMPCA study. Annals of oncology : official journal of the
European Society for Medical Oncology. 2016;27(5):868-874.